Abstract
BackgroundDenosumab is a fully human monoclonal antibody that targets the receptor activator of nuclear factor kappa B ligand (RANKL) and blocks its binding to RANK, preventing osteoclasts from resorbing bone...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
